IL256274B2 - Methods of treating epithelioid cell tumors - Google Patents

Methods of treating epithelioid cell tumors

Info

Publication number
IL256274B2
IL256274B2 IL256274A IL25627417A IL256274B2 IL 256274 B2 IL256274 B2 IL 256274B2 IL 256274 A IL256274 A IL 256274A IL 25627417 A IL25627417 A IL 25627417A IL 256274 B2 IL256274 B2 IL 256274B2
Authority
IL
Israel
Prior art keywords
composition
individual
albumin
nanoparticles
sirolimus
Prior art date
Application number
IL256274A
Other languages
English (en)
Hebrew (he)
Other versions
IL256274A (en
IL256274B (en
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL256274(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of IL256274A publication Critical patent/IL256274A/en
Publication of IL256274B publication Critical patent/IL256274B/en
Publication of IL256274B2 publication Critical patent/IL256274B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL256274A 2015-06-29 2017-12-12 Methods of treating epithelioid cell tumors IL256274B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186252P 2015-06-29 2015-06-29
PCT/US2016/040170 WO2017004249A1 (en) 2015-06-29 2016-06-29 Methods of treating epithelioid cell tumors

Publications (3)

Publication Number Publication Date
IL256274A IL256274A (en) 2018-02-28
IL256274B IL256274B (en) 2022-10-01
IL256274B2 true IL256274B2 (en) 2023-02-01

Family

ID=57609139

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256274A IL256274B2 (en) 2015-06-29 2017-12-12 Methods of treating epithelioid cell tumors

Country Status (26)

Country Link
US (3) US10973806B2 (pl)
EP (2) EP3313401B1 (pl)
JP (3) JP6987644B2 (pl)
KR (2) KR102798594B1 (pl)
CN (3) CN116585310A (pl)
AU (2) AU2016285720C1 (pl)
BR (1) BR112017027954B1 (pl)
CA (1) CA2990693C (pl)
CL (1) CL2017003456A1 (pl)
CY (1) CY1124926T1 (pl)
DK (1) DK3313401T3 (pl)
EA (2) EA036790B1 (pl)
ES (2) ES2897991T3 (pl)
HR (2) HRP20250141T1 (pl)
HU (2) HUE070408T2 (pl)
IL (1) IL256274B2 (pl)
LT (1) LT3313401T (pl)
MX (2) MX381140B (pl)
PL (2) PL3998069T3 (pl)
PT (1) PT3313401T (pl)
RS (2) RS66503B1 (pl)
SG (1) SG10202107198SA (pl)
SI (1) SI3313401T1 (pl)
SM (2) SMT202100642T1 (pl)
WO (1) WO2017004249A1 (pl)
ZA (1) ZA201708567B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
BR112013027674A2 (pt) 2011-04-28 2016-09-06 Abraxis Bioscience Llc "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EP3313401B1 (en) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
SG11202011462SA (en) * 2018-05-22 2020-12-30 Abraxis Bioscience Llc Methods and compositions for treating pulmonary hypertension
CN109182519B (zh) * 2018-09-17 2019-06-14 中国人民解放军南京军区南京总医院 一种用于诊断acta2-mitf易位性血管周上皮样细胞肿瘤的探针组合及其应用
EP3941551A4 (en) * 2019-03-19 2023-01-18 Abraxis BioScience, LLC SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES WITH AN MTOR INHIBITOR AND ALBUMIN FOR THE TREATMENT OF DISEASES
KR20220106758A (ko) * 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
EP4058000A4 (en) * 2019-11-11 2024-02-28 Abraxis BioScience, LLC BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
WO2021096997A1 (en) * 2019-11-11 2021-05-20 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
CN116600789A (zh) * 2020-06-19 2023-08-15 耶鲁大学 用于诱导耐受性的聚合胆汁酸酯纳米颗粒
WO2022254587A1 (ja) * 2021-06-01 2022-12-08 昭和電工マテリアルズ株式会社 プリプレグ、積層板、金属張り積層板、プリント配線板、半導体パッケージ並びにプリプレグの製造方法及び金属張り積層板の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20070116761A1 (en) 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP3746293B2 (ja) 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ES2435944T3 (es) 1997-06-27 2013-12-26 Abraxis Bioscience, Llc Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
CA2371912C (en) 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
KR20140148502A (ko) 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009532503A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
BRPI0622006A2 (pt) 2006-08-31 2011-12-20 Abraxis Bioscience Llc usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
AU2013204187B2 (en) 2007-03-07 2015-10-01 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
NZ593343A (en) 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2010083298A1 (en) 2009-01-14 2010-07-22 Health Research Inc. Methods and compositions containing mtor inhibitors for enhancing immune responses
BRPI1008955A2 (pt) 2009-03-13 2015-09-01 Abraxis Bioscience Llc Terapia de combinação com derivados de tiocolchicina.
EP2416650B1 (en) 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
JP2013503174A (ja) 2009-08-25 2013-01-31 アブラクシス バイオサイエンス， エルエルシー タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
JP2013527232A (ja) 2010-06-02 2013-06-27 アブラクシス バイオサイエンス， エルエルシー 膀胱がんの処置方法
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
MY166014A (en) 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
BR112013027674A2 (pt) 2011-04-28 2016-09-06 Abraxis Bioscience Llc "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
NZ630239A (en) 2013-02-11 2017-08-25 Abraxis Bioscience Llc Methods of treating melanoma
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
AU2014228386B2 (en) 2013-03-13 2018-11-29 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
EP2971122B1 (en) 2013-03-15 2020-08-26 Memorial Sloan Kettering Cancer Center Biomarkers for response to rapamycin analogs
WO2014144405A1 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
EP2986318A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
EP3313401B1 (en) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
EP3313409A4 (en) 2015-06-29 2018-12-26 Abraxis BioScience, LLC Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
CA2990726A1 (en) 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
JP2018527308A (ja) 2015-06-29 2018-09-20 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物のためのバイオマーカー
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer
WO2017201189A1 (en) 2016-05-17 2017-11-23 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
CN110022876A (zh) 2016-09-28 2019-07-16 阿布拉科斯生物科学有限公司 治疗线粒体和代谢病症的方法
EP3522887A4 (en) 2016-10-07 2020-06-10 Abraxis BioScience, LLC METHODS OF TREATING BILARIAN CANCER
MX2019003988A (es) 2016-10-10 2019-08-14 Abraxis Bioscience Llc Formulaciones de nanoparticulas y sus metodos de fabricacion y uso.
US20180374583A1 (en) 2017-05-16 2018-12-27 Abraxis Bioscience, Llc Nomogram and survival predictions for pancreatic cancer
CN111683657A (zh) 2017-12-19 2020-09-18 阿布拉科斯生物科学有限公司 利用纳米颗粒mTOR抑制剂联合疗法治疗结肠癌的方法
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
SG11202011462SA (en) 2018-05-22 2020-12-30 Abraxis Bioscience Llc Methods and compositions for treating pulmonary hypertension
EP3941551A4 (en) 2019-03-19 2023-01-18 Abraxis BioScience, LLC SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES WITH AN MTOR INHIBITOR AND ALBUMIN FOR THE TREATMENT OF DISEASES
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
EP4058000A4 (en) 2019-11-11 2024-02-28 Abraxis BioScience, LLC BIOMARKERS FOR NANOPARTICLE COMPOSITIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHARLOTTE BENSON ET AL,, A RETROSPECTIVE STUDY OF PATIENTS WITH MALIGNANT PECOMA RECEIVING TREATMENT WITH SIROLIMUS OR TEMSIROLIMUS: THE ROYAL MARSDEN HOSPITAL EXPERIENCE, 1 January 2014 (2014-01-01) *
EL-HASHEMITE NISREEN ET AL,, MUTATION INTSC2AND ACTIVATION OF MAMMALIAN TARGET OF RAPAMYCIN SIGNALLING PATHWAY IN RENAL ANGIOMYOLIPOMA, 31 December 2003 (2003-12-31) *
HENRY B ARMAH ET AL,, MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) OF THE UTERUS WITH LATE RENAL AND PULMONARY METASTASES: A CASE REPORT WITH REVIEW OF THE LITERATURE, 1 January 2007 (2007-01-01) *
MARK A. DICKSON ET AL,, EXTRARENAL PERIVASCULAR EPITHELIOID CELL TUMORS (PECOMAS) RESPOND TO MTOR INHIBITION: CLINICAL AND MOLECULAR CORRELATES, 21 September 2012 (2012-09-21) *

Also Published As

Publication number Publication date
SMT202500058T1 (it) 2025-03-12
AU2021286245A1 (en) 2022-01-06
DK3313401T3 (da) 2021-11-15
RS66503B1 (sr) 2025-03-31
CN108024999A (zh) 2018-05-11
CN116473964A (zh) 2023-07-25
EA202092187A1 (ru) 2021-08-31
AU2016285720C1 (en) 2022-02-03
SG10202107198SA (en) 2021-08-30
LT3313401T (lt) 2022-01-10
ES3009356T3 (en) 2025-03-26
EA201890157A1 (ru) 2018-09-28
MX2021002455A (es) 2021-05-14
CA2990693C (en) 2024-02-27
PT3313401T (pt) 2021-11-17
EP3998069B1 (en) 2024-12-11
US20180177770A1 (en) 2018-06-28
PL3998069T3 (pl) 2025-03-31
KR20230165356A (ko) 2023-12-05
JP6987644B2 (ja) 2022-01-05
HRP20250141T1 (hr) 2025-03-28
ES2897991T3 (es) 2022-03-03
KR102606071B1 (ko) 2023-11-27
CA2990693A1 (en) 2017-01-05
EA036790B1 (ru) 2020-12-22
CL2017003456A1 (es) 2018-05-11
AU2021286245B2 (en) 2024-01-18
US20210322391A1 (en) 2021-10-21
RS62743B1 (sr) 2022-01-31
US10973806B2 (en) 2021-04-13
SMT202100642T1 (it) 2022-03-21
CY1124926T1 (el) 2023-01-05
EP3313401A4 (en) 2019-02-13
BR112017027954A2 (pt) 2018-08-28
HRP20211718T1 (hr) 2022-03-04
HK1247094A1 (zh) 2018-09-21
HUE057175T2 (hu) 2022-04-28
EP3998069C0 (en) 2024-12-11
EP3313401A1 (en) 2018-05-02
IL256274A (en) 2018-02-28
IL256274B (en) 2022-10-01
KR102798594B1 (ko) 2025-04-18
NZ738936A (en) 2023-08-25
JP2022043090A (ja) 2022-03-15
EP3313401B1 (en) 2021-10-06
KR20180021836A (ko) 2018-03-05
SI3313401T1 (sl) 2022-04-29
MX2017016322A (es) 2018-05-02
US12133844B2 (en) 2024-11-05
US20250248978A1 (en) 2025-08-07
BR112017027954B1 (pt) 2023-10-03
AU2016285720A1 (en) 2018-02-01
JP2018521057A (ja) 2018-08-02
PL3313401T3 (pl) 2022-02-07
WO2017004249A1 (en) 2017-01-05
MX381140B (es) 2025-03-12
JP7351888B2 (ja) 2023-09-27
ZA201708567B (en) 2021-03-31
EP3998069A1 (en) 2022-05-18
JP7738612B2 (ja) 2025-09-12
HUE070408T2 (hu) 2025-06-28
NZ777582A (en) 2025-03-28
JP2023175811A (ja) 2023-12-12
AU2016285720B2 (en) 2021-09-30
CN116585310A (zh) 2023-08-15

Similar Documents

Publication Publication Date Title
AU2021286245B2 (en) Methods of treating epithelioid cell tumors
AU2016285727B2 (en) Biomarkers for nanoparticle compositions
US20240009323A1 (en) Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
JP2018521057A5 (pl)
CA3140146A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
HK40074948B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HK40074948A (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
NZ738936B2 (en) Methods of treating epithelioid cell tumors
HK1247094B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
EA045904B1 (ru) Способы лечения эпителиоидноклеточных опухолей